Bioverativ Hits The Street Ready To Expand In Blood Disorders

Listen to this article

Bioverativ will spin out from Biogen Feb. 1 as a biotech focused on rare blood disorders, particularly hemophilia. With two marketed drugs, a lifecycle management strategy and leverage to bring in new assets, CEO John Cox says the company is ready to go it alone.

Bioverativ Inc. – a new biotech focused on rare blood disorders – expects to deliver long-term growth by expanding the use of its two long-acting hemophilia drugs, a broad lifecycle management strategy and business development ambitions. The company is scheduled to spinout from Biogen Inc. as an independent company Feb. 1, with full trading to resume on NASDAQ under the symbol BVV the next day.

CEO John Cox talked about the company’s independent growth strategy during an interview Jan. 11 at the J.P. Morgan Healthcare...

Test Regulatory Recap: Ireland To See Earlier Off-Patent Medicines Launches As A State Deal Passes - Clone

Feb 04 2026

• By Urtė Fultinavičiūtė

Also, Latest News From Europe, Canada, Saudi Arabia, Finland, China, And The US

Syndax Achieves Commercial Status As Incyte-Partnered GVHD Drug Gets FDA Nod

Aug 15 2024

• By Alaric DeArment

US FDA approval of Niktimvo for third-line chronic GVHD, a competitor to Sanofi’s Rezurock, came less than two months ahead of anticipated approval of Syndax’s leukemia drug revumenib.

Pfizer’s Hemophilia A Gene Therapy Superior To Prophylaxis In Phase III

Jul 24 2024

• By Jessica Merrill

The company’s giroctocogene fitelparvovec, partnered with Sangamo, could compete with BioMarin’s hemophilia A gene therapy Roctavian, but longer-term data may be needed.